What's Going On With Sarepta Therapeutics Stock Monday? - Sarepta Therapeutics (NASDAQ:SRPT)

Sarepta Therapeutics (NASDAQ:SRPT) Stock Price Up 13.9% on Analyst Upgrade

Sarepta Therapeutics (NASDAQ:SRPT) Shares Up 13.9% After Analyst Upgrade

What's Going On With Sarepta Therapeutics Stock Monday? - Sarepta Therapeutics (NASDAQ:SRPT)

Sarepta Therapeutics Inc. (NASDAQ:SRPT) on Monday released topline three-year functional results from Part 1-treated patients in the EMBARK (Study SRP-9001-301) Phase 3 study of Elevidys (delandistrogene moxeparvovec-rokl) in ambulatory individuals with Duchenne muscular dystrophy. Three years after treatment, patients who received Elevidys in Part 1 of EMBARK demonstrated statistically significant, clinically meaningful, and durable efficacy ac…

Sarepta eyes Elevidys sales comeback with positive Phase III data

William Blair analysts view Elevidys’ three-year outcome as a win for Sarepta, though they remain sceptical on the readout’s sales impact.The post Sarepta eyes Elevidys sales comeback with positive Phase III data appeared first on Clinical Trials Arena.

Sarepta touts three-year Duchenne gene therapy data after patient deaths rattled field

Sarepta said the effects of its Duchenne muscular dystrophy gene therapy were durable three years after treatment, based on longer-term findings from patients in its key clinical trial. The data come after a tumultuous year ...

Sarepta Therapeutics (NASDAQ:SRPT) Shares Up 13.9% on Analyst Upgrade

Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Get Free Report)’s share price shot up 13.9% on Monday after Wedbush raised their price target on the stock from $32.00 to $34.00. Wedbush currently has an outperform rating on the stock. Sarepta Therapeutics traded as high as $24.46 and last traded at $24.0730. 1,556,026 shares were traded during mid-day […]

Sarepta Stock Rises on Positive 3-Year Study Results for Elevidys